AgomAb Therapeutics NV (NASDAQ:AGMB)
| Market Cap | 429.93M-40.1% |
| Revenue (ttm) | 0 |
| Net Income | -35.68M |
| EPS | -0.79 |
| Shares Out | 49.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,520.587 |
| Open | 8.88 |
| Previous Close | 8.80 |
| Day's Range | 8.63 - 9.15 |
| 52-Week Range | 7.97 - 17.82 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | 35.00(+300.92%) |
| Earnings Date | Mar 3, 2027 |
AgomAb Therapeutics NV has a live Insider Score.
Scored on 7 qualifying trades from 3 insiders in the last 90 days.
About AGMB
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AGMB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AGMB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AGMB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AGMB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AGMB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AGMB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AGMB
| ETF | Est. Holding Size |
|---|---|
| SBIOALPS Medical Breakthroughs ETF | $546.29K |
Estimated from each fund’s disclosed top holdings × AUM
AGMB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AGMB’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score